Broker's call: Sun Pharmaceutical Ind (Buy)

| Updated on March 09, 2020 Published on March 10, 2020

ICICI Securities

Sun Pharmaceutical Ind (Buy)

CMP: ₹392.6

Target: ₹478

Sun Pharmaceutical Industries Ltd is a pharmaceuticals company. The company’s business segments include US business, Indian branded generics business, emerging markets, global consumer healthcare business and active pharmaceutical ingredients (API). Its rest-of-the-world segment includes Western Europe, Canada, Australia, New Zealand and other markets. The company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs.

Sun Pharmaceutical Industries’ stock price has corrected about 20 per cent in the past two months and we believe the key concerns of slow ramp-up of specialty portfolio and likely negative outcome in ensuing US DOJ (Department of Justice) case for generic drug price fixing have been factored in the current valuations.

Resolution of generic drug price fixing case by Sandoz with US DOJ indicates a possible resolution by Sun Pharma (including Taro) which could be positive in our view as it would remove a major overhang from the stock. The company continues to focus on cost rationalisation measures and improving its product mix. Strong performance in India business and stability in base business margin despite slow ramp-up in specialty portfolio are likely to continue.

Upgrade to ‘buy’ with revised target price of ₹478/share (earlier ₹445/share).

Key downside risks are: Regulatory hurdles and adverse outcome on generic price fixing case with US DOJ with significant penalty.

Published on March 10, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.